Loading organizations...
Loading organizations...
Aphelion Capital: Healthcare venture capital firm invests in early-stage medtech & digital health companies with capital-efficient products.
Aphelion Capital is a healthcare venture capital firm based in Mill Valley, California, that invests in early and mid-stage medical device, digital health, and biotechnology companies. The firm manages five closed funds, operating with an estimated headcount of 11 to 500 employees, and participates in seed through Series C rounds by leading $20 million syndicates or acting as a $50,000 solo investor. Its investment strategy targets capital-efficient diagnostics and healthcare information technology solutions that aim to reduce systemic costs. The firm's portfolio includes medical technology developers such as Silk Road Medical, Relievant Medsystems, Eargo, and Minerva Surgical. Recent exits feature Boston Scientific acquiring Relievant Medsystems for an $850 million upfront payment in 2023 and purchasing Silk Road Medical for approximately $1.16 billion in 2024. Aphelion Capital was originally founded in 2005 by managing partner Ned Scheetz.
Key people at Aphelion Capital.
Key people at Aphelion Capital.
Aphelion Capital is a venture capital investment firm specializing primarily in the medical technology sector. Its mission centers on investing in innovative medical technologies and health and wellness products that aim to reduce healthcare costs and improve clinical outcomes. The firm invests across all stages—from seed to late stage—with a preference for companies that have low capital requirements and shorter timelines to market. Aphelion Capital leverages deep industry knowledge and networks to support entrepreneurs and enhance returns, focusing on technologies that deliver better health outcomes at the same or lower cost to the healthcare system[1][2][3].
Founded in 2005 and based in California (Mill Valley and San Francisco areas), Aphelion Capital was established to address the evolving healthcare landscape through venture investments. Key figures include Ned Scheetz (Founder and Managing Partner), along with other partners such as John Kim and Jake Martellaro. Over time, the firm has evolved to emphasize collaborative capital, working closely with entrepreneurs to provide not only funding but strategic support and access to a broad network within the medical technology ecosystem[1][4][5].
Aphelion Capital rides the trend of healthcare innovation driven by the need to reduce systemic costs and improve patient outcomes. The timing is critical as healthcare systems globally face increasing financial pressures and demand for more efficient, patient-centered solutions. By focusing on medical technologies with shorter development cycles and lower capital needs, Aphelion aligns with market forces favoring agile innovation. Their influence extends beyond funding, shaping the startup ecosystem by supporting technologies that could transform healthcare delivery and wellness[1][2][3].
Looking ahead, Aphelion Capital is likely to continue emphasizing investments in disruptive medical technologies that address cost and outcome challenges in healthcare. Trends such as digital health, personalized medicine, and value-based care will shape their investment focus. Their collaborative capital model and deep sector expertise position them to remain influential in nurturing startups that can scale efficiently and impact the healthcare system positively. As healthcare innovation accelerates, Aphelion’s role as a strategic partner will be increasingly vital for entrepreneurs navigating complex regulatory and market environments[3][4].
